VRK1: a protein that reduces the survival of patients with neuroblastoma

December 11, 2020

Researchers from the Departments of Cell Biology and Medical Physiology at the University of Seville have identified that a high expression of the human protein VRK1 is associated with tumour aggressiveness and low survival among neuroblastoma patients. Aggressive neuroblastoma is one of the most common solid childhood cancers and causes disproportionately high mortality in affected children. Although advances have been made in recent years, the outlook for recovery in children affected by aggressive neuroblastoma remains low and a better understanding of this tumour's biology is needed in order to create new treatments and prognostic tools.

Researchers have characterised the function of VRK1 in neuroblastoma tumour cells and have determined that this protein is essential for tumour cell growth and proliferation. "By studying the expression of this protein in tumours, we were able to identify a priori patients where tumour progression is going to be worse, even in groups where current tools do not predict that behaviour," notes Francisco M. Vega.

This study suggests that VRK1 works in conjunction with other oncogenes such as MYCN, which is heavily affected in this cancer, to boost tumour progression and make it more aggressive. Therefore, the researchers suggest that inhibiting VRK1 could be a new strategy for cancer therapy in neuroblastoma. "VRK1 is a protein kinase. These are some of the best targets for targeted cancer treatment, as we can potentially produce inhibitors in the laboratory that override their activity," explains Professor Vega.
-end-
This study was made possible thanks to funding from the Ministry of Science and the Andalusian Regional Government. In addition, the authors are especially grateful to family members and patients with this type of cancer for their cooperation through the Association of Family and Friends of Patients with Neuroblastoma (NEN).

This study is part of the doctoral thesis of Dr. Ana Colmenero-Repiso and was carried out at the Institute of Biomedicine of Seville (IBiS) by researchers from the Department of Cell Biology and the Department of Medical Physiology of the University of Seville, directed by Dr. Francisco M. Vega and Dr. Ricardo Pardal. In addition, it benefited from the international collaboration of researchers from the German Cancer Centre (DKFZ) in Heidelberg, Germany.

University of Seville

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.